苏州艾隆科技股份有限公司 独立董事关于第四届董事会第十二次会议相关事项的 独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司 独立董事规则》等法律、行政法规、部门规章和规范性文件，以及《苏州艾隆 科技股份有限公司章程》（以下简称"《公司章程》"）等有关规定，作为苏 州艾隆科技股份有限公司（以下简称"公司"）的独立董事，我们认真审阅了 公司第四届董事会第十二次会议资料后，基于独立客观判断立场，本着审慎负 责的态度，现就会议相关事项发表如下独立意见： 经审阅公司《2023年半年度募集资金存放与实际使用情况的专项报告》，我 们一致认为：公司募集资金的使用符合中国证监会、上海证券交易所关于上市公 司募集资金存放与使用的相关规定，如实反映了公司2023年半年度募集资金实际 存放与使用情况，不存在变相改变募集资金用途和损害股东利益的情形，不存在 募集资金存放和使用违规的情形。我们同意公司2023年半年度募集资金存放及实 际使用情况的事项。 独立董事： 一、关于《2023年半年度募集资金存放与实际使用情况的专项报告》的独 立意见 二、《关于2023年度日常关联交易额度预计的议案》的独立意见 经审阅公 ...

海通证券股份有限公司关于苏州艾隆科技股份有限公司 2023 年半年度持续督导跟踪报告 | 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：艾隆科技 | | --- | --- | | 保荐代表人姓名：丁昊、戴文俊 | 被保荐公司代码：688329 | 经中国证券监督管理委员会《关于同意苏州艾隆科技股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕250 号）同意注册，苏州艾隆科技股份 有限公司（以下简称"上市公司"、"公司"或"发行人"）首次公开发行股票 1,930.00 万股，每股面值人民币 1 元，每股发行价格人民币 16.81 元，募集资金总额为人民 币 32,443.30 万元，扣除发行费用后，实际募集资金净额为人民币 27,437.65 万元。 本次发行证券已于 2021 年 3 月 29 日在上海证券交易所上市。海通证券股份有限 公司（以下简称"保荐机构"或"海通证券"）担任其持续督导保荐机构，持续督导期 间为 2021 年 3 月 29 日至 2024 年 12 月 31 日。 在 2023 年 1 月 1 日至 2023 年 6 月 30 日持续督导期内（以下简称"本持续 ...

证券代码：688329 证券简称：艾隆科技 公告编号：2023-038 苏州艾隆科技股份有限公司 表决结果：同意：3 票；反对：0 票；弃权：0 票。 第四届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 苏州艾隆科技股份有限公司（以下简称"公司"）第四届监事会第十二次会 议于 2023 年 8 月 11 日在公司会议室以现场方式召开，会议通知已于 2023 年 8 月 4 日通过邮件的方式送达各位监事。本次会议由监事会主席张春兰女士主持， 会议应出席监事 3 名，实际出席 3 名。会议召开符合《中华人民共和国公司法》 及《公司章程》的规定。 二、监事会会议审议情况 （一）审议通过《关于<2023 年半年度报告及半年度报告摘要>的议案》 监事会认为：（1）公司 2023 年半年度报告及半年度报告摘要的编制和审议 程序规范合法，符合法律、法规、公司章程及监管机构的规定。 （2）公司 2023 年半年度报告及半年度报告摘要公允反映了公司报告期内的 财务状况和经营成果，所包含的 ...

海通证券股份有限公司关于苏州艾隆科技股份有限公司 2023年度日常关联交易预计事项的核查意见 海通证券股份有限公司（以下简称"海通证券"或"保荐机构"）作为苏州 艾隆科技股份有限公司（以下简称"艾隆科技"或"公司"）首次公开发行股票 并在科创板上市的持续督导保荐机构，根据《证券发行上市保荐业务管理办法》 《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要求》《上海 证券交易所股票上市规则》等有关规定，对公司2023年度日常关联交易预计事项 进行了核查，具体情况如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于2023年8月11日召开了第四届董事会第十二次会议和第四届监事会第 十二次会议，审议通过了《关于2023年度日常关联交易额度预计的议案》，本次 日常关联交易额度预计金额合计为2,500万元人民币，出席会议的董事、监事一致 表决通过该议案。审议程序符合《中华人民共和国公司法》《中华人民共和国证 券法》等相关法律法规的规定。本次日常关联交易额度预计事项无需提交公司股 东大会审议。 公司全体独立董事发表了明确同意的独立意见。独立董事认为：本次公司 2023年度日常关联交易额度 ...

证券代码：688329 证券简称：艾隆科技 公告编号：2023-039 苏州艾隆科技股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》《上 海证券交易所科创板股票上市规则》等有关法律、法规及相关文件的规定，苏 州艾隆科技股份有限公司（以下简称"公司"或"本公司"）就2023年半年度 募集资金存放与实际使用情况的专项报告说明如下： 一、募集资金基本情况 二、募集资金管理情况 （一）募集资金管理情况 为规范公司募集资金管理和使用，保护投资者权益，按照《中华人民共和 国公司法》《中华人民共和国证券法》《上海证券交易所科创板股票上市规则》 《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》和 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关 法律、法规和规范性文件的规定，结合公司实际情况， ...

证券代码：688329 证券简称：艾隆科技 公告编号：2023-036 苏州艾隆科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司已于 2023 年 4 月 21 日披露公司 2022 年年度报告；于 2023 年 4 月 28 日披露公司 2023 年第一季度报告。为便于广大投资者更全面深入地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 6 月 21 日（星期三）下午 14:00-15:00 举行 2022 年度暨 2023 年第一季度业绩说明会， 就投资者关心的问题进行交流，欢迎广大投资者积极参与。 本次业绩说明会以网络互动形式召开，公司将针对 2022 年度及 2023 年第一 季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披 露允许的范围内就投资者普遍关注的问题进行回答。 会议召开时间：2023 年 6 月 21 日(星期三)下午 14:00-15:00 会 ...

2022 年第三季度报告 证券代码：688329 证券简称：艾隆科技 苏州艾隆科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 136,021,808.65 | 76.88 | 302,015,219.68 | 45.64 | ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[13]. - The company has set a revenue target of RMB 1.2 billion for the full year 2022, indicating an expected growth of 15% compared to 2021[13]. - The company's operating revenue for the first half of the year reached ¥165,993,411.03, an increase of 27.23% compared to the same period last year[19]. - Net profit attributable to shareholders increased by 62.32% year-on-year, amounting to ¥30,212,509.22[19]. - The company achieved a revenue of 166 million RMB in the first half of 2022, representing a year-on-year growth of 27.23%[80]. - The net profit attributable to shareholders reached 30.21 million RMB, marking a 62.32% increase compared to the same period last year[80]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2022, representing a year-over-year growth of 25%[130]. - The total comprehensive income for the first half of 2022 was CNY 30,376,985.88, compared to CNY 15,893,862.74 in the same period last year[180]. User Growth - User data showed an increase in active users to 1.2 million, up from 1 million in the same period last year, marking a growth of 20%[13]. - User data showed a growth in active users, reaching 5 million, which is a 20% increase compared to the previous year[128]. - User data showed a growth in active users, reaching 10 million, which is a 15% increase compared to the previous year[130]. Product Development and Innovation - New product launches included a state-of-the-art medical device that is expected to generate an additional RMB 100 million in revenue by the end of 2022[13]. - The company is actively expanding into new application areas beyond its current focus on pharmaceuticals and medical supplies[26]. - The company has developed a series of automated pharmacy products for emergency departments, including rapid dispensing machines and intelligent storage cabinets, enhancing drug management efficiency and reducing patient wait times[29]. - The company is currently developing an integrated automated pharmacy system capable of processing over 6,000 prescriptions daily, which is now in the industrialization phase[61]. - The company is also working on a personalized Chinese medicine preparation system, which is a domestic first and is currently in the product development enhancement stage[62]. - New product launches are expected to contribute an additional 200 million in revenue by the end of the year[128]. - New product launches are expected to contribute an additional 300 million in revenue by the end of the fiscal year[130]. Market Expansion - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2022[13]. - Market expansion plans include entering three new international markets by Q4 2022, aiming for a 5% market share in each[128]. - Market expansion plans include entering three new international markets by Q4 2022, aiming for a 10% market share in each[130]. Research and Development - Research and development expenses increased to RMB 50 million, accounting for 10% of total revenue, reflecting a commitment to innovation[13]. - The total R&D investment for the period was approximately ¥18.76 million, representing a 5.55% increase compared to the previous year[64]. - Research and development expenses increased by 5.55% to ¥18,758,770.97, reflecting the company's commitment to innovation[98]. - The company has developed 8 core key technologies related to intelligent management of medical materials, with a total of 176 authorized patents[61]. - The company has applied for a total of 853 patents, with 399 patents granted as of the report date[81]. Strategic Acquisitions - The company has completed a strategic acquisition of a local competitor for RMB 200 million, aimed at enhancing its market share[13]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 300 million allocated for potential deals[128]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of acquiring two companies by the end of the year[130]. Operational Efficiency - The company plans to implement a new digital marketing strategy to increase customer engagement and drive sales growth[13]. - The company has set a target to reduce operational costs by 10% through efficiency improvements in the supply chain[128]. - The management emphasized the importance of compliance with regulatory requirements to avoid any potential legal issues in the future[128]. Financial Management - The company has received government support for its "integrated smart pharmacy service upgrade project," recognized as a benchmark demonstration project[81]. - The company utilized RMB 160,000,000 of raised funds for supplementary working capital, indicating a strategic move to enhance liquidity[145]. - The total amount of guarantees provided by the company, excluding guarantees to subsidiaries, is 7,000,000.00 RMB, which accounts for 0.87% of the company's net assets[141]. - The cumulative amount of funds raised through the initial public offering is 324,433,000.00 RMB, with a net amount of 274,376,492.52 RMB after deducting issuance costs[144]. Risks and Challenges - The management highlighted potential risks including supply chain disruptions and regulatory changes, which could impact future performance[13]. - The company faces risks related to core technology and personnel turnover, which could impact product development and operational efficiency[85]. - The company faces risks related to changes in government subsidy policies, which could adversely affect its operating performance and profitability[96]. - The company acknowledges the risk of industry competition intensifying as more capital, talent, and technology enter the market[85]. Shareholder and Governance - The board of directors confirmed that there are no significant non-operating fund occupations by controlling shareholders[13]. - The company has established a long-term incentive mechanism to align the interests of shareholders, the company, and employees[82]. - The company has made commitments regarding share repurchase and measures to avoid dilution of immediate returns[134]. - The company has committed to ensuring that any share reductions after the lock-up period will not be below the IPO price[126].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 43,109,552.26, representing a year-on-year increase of 7.91%[5] - The net profit attributable to shareholders was CNY -393,057.54, a decrease of 106.67% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -1,855,938.84, down 132.68% year-on-year[5] - Total revenue for Q1 2022 was CNY 43,109,552.26, an increase of 5.8% compared to CNY 39,949,459.16 in Q1 2021[18] - Total operating costs for Q1 2022 were CNY 46,943,846.78, up 10.4% from CNY 42,460,385.47 in Q1 2021[19] - Operating profit for Q1 2022 was a loss of CNY 478,604.53, compared to a profit of CNY 5,620,032.34 in Q1 2021[19] - Net profit for Q1 2022 was a loss of CNY 877,212.95, down from a profit of CNY 4,154,655.62 in Q1 2021[20] - Basic and diluted earnings per share for Q1 2022 were both CNY -0.01, compared to CNY 0.10 in Q1 2021[21] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,204,561,410.05, an increase of 5.69% from the end of the previous year[6] - Total assets as of Q1 2022 were CNY 1,204,561,410.05, an increase from CNY 1,139,692,222.35 in the previous year[17] - Total liabilities for Q1 2022 were CNY 393,760,364.73, compared to CNY 332,554,858.78 in Q1 2021, reflecting a growth of 18.4%[17] - Non-current assets totaled CNY 507,204,253.39 in Q1 2022, up from CNY 443,858,525.78 in Q1 2021[17] - The total liabilities and equity structure remains stable, with no significant changes reported in the financial statements[15] Cash Flow - The net cash flow from operating activities was CNY 6,238,788.63, with no applicable comparison[6] - Cash flow from operating activities showed a significant decline, impacting liquidity and operational flexibility[21] - The net cash flow from operating activities for Q1 2022 was $6,238,788.63, compared to a negative $5,974,945.98 in Q1 2021, indicating a significant improvement[23] - Cash inflow from operating activities totaled $151,053,926.41 in Q1 2022, up from $97,643,895.27 in Q1 2021, representing a year-over-year increase of approximately 54.5%[22] - Cash outflow from operating activities increased to $144,815,137.78 in Q1 2022, compared to $103,618,841.25 in Q1 2021, reflecting a rise of about 39.8%[22] - Cash flow from investment activities showed a net inflow of $50,706,706.94 in Q1 2022, a recovery from a net outflow of $28,077,537.53 in Q1 2021[23] - Cash inflow from investment activities reached $133,014,779.44 in Q1 2022, significantly higher than $10,025,315.07 in Q1 2021[23] - The company reported a cash balance of $206,477,561.64 at the end of Q1 2022, down from $396,036,913.67 at the end of Q1 2021[23] - Total cash outflow from financing activities was $2,380,609.46 in Q1 2022, compared to $31,158,323.04 in Q1 2021, indicating a decrease of approximately 92.4%[23] - The company’s cash flow from financing activities resulted in a net outflow of $2,344,953.73 in Q1 2022, contrasting with a net inflow of $273,806,687.66 in Q1 2021[23] Shareholder Information - The company had a total of 4,335 common shareholders at the end of the reporting period[10] - The top three shareholders held a combined 46.97% of the company's shares, with Zhang Yinhua holding 29.86%[10] - The company reported a total of 4,745,000 shares held by major shareholder Wen Qingnan, representing a significant stake in the company[12] - The top ten shareholders collectively hold a substantial number of shares, with the largest being Zhuhai Longmen Capital Management Co., Ltd. at 3,865,000 shares[12] Research and Development - Research and development expenses totaled CNY 6,249,043.84, accounting for 14.50% of operating revenue, a decrease of 3.89 percentage points year-on-year[6] - The company has not disclosed any new product developments or market expansion strategies during this reporting period[13]

Financial Performance - The company's operating revenue for 2021 was approximately RMB 389.32 million, representing a year-on-year increase of 25.60% compared to RMB 309.98 million in 2020[24]. - The net profit attributable to shareholders of the listed company increased by 33.40% year-on-year to approximately RMB 95.59 million, up from RMB 71.66 million in 2020[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 42.20% year-on-year to approximately RMB 88.91 million[24]. - The total assets of the company increased by 43.18% year-on-year to approximately RMB 1.14 billion, up from RMB 795.96 million in 2020[25]. - The net assets attributable to shareholders of the listed company increased by 76.31% year-on-year to approximately RMB 803.13 million[25]. - The basic earnings per share for 2021 was RMB 1.32, a 6.45% increase from RMB 1.24 in 2020[26]. - The company's gross profit margin for the main business was 60.16%, which increased by 0.73 percentage points year-on-year[113]. - The revenue from the automation pharmacy segment was CNY 279,202,574.01, with a gross profit margin of 64.35%, showing a decrease of 1.25 percentage points[113]. - The company achieved a total R&D investment of ¥39,611,447.29 in the current year, representing a 22.86% increase compared to ¥32,242,358.85 in the previous year[83]. Cash Flow and Dividends - The company plans to distribute a cash dividend of 5 yuan (including tax) for every 10 shares, totaling 38.6 million yuan, which represents 40.38% of the net profit attributable to shareholders for 2021[5]. - The net cash flow from operating activities decreased by 66.09% year-on-year to approximately RMB 39.75 million, primarily due to an increase in advance payments for orders[27]. - The company’s cash flow must meet operational and developmental needs to implement cash dividends[194]. - The company will conduct profit distribution at least once a year, subject to meeting specific conditions such as profitability and positive retained earnings[194]. - The company has established a stable profit distribution policy, ensuring reasonable returns for investors while maintaining normal operations and long-term development[193]. Research and Development - The research and development expenditure accounted for 10.17% of operating revenue, slightly down from 10.40% in 2020[26]. - The company applied for 830 patents and obtained 372 patents by the end of 2021, enhancing its core competitiveness through innovation[39]. - The company has developed 8 core key technologies, with a total of 161 authorized invention patents, enhancing its capabilities in smart medical management[77]. - The company is currently testing an AI-based empty bottle recognition system for anesthesia drugs, which is in the trial production stage and aims to enhance safety in operating rooms[87]. - The company is focusing on expanding its market presence through innovative products and technologies, aiming for significant growth in the healthcare sector[85]. Market and Industry Outlook - The medical equipment industry is expected to accelerate growth starting in 2022, driven by the ongoing development of new medical infrastructure since 2020[41]. - The company is positioned to benefit from increasing hospital numbers and rising government healthcare spending, which are driving industry demand[150]. - The healthcare infrastructure development is expected to accelerate growth in the medical equipment industry starting from 2022, providing opportunities for the company[151]. - The company plans to expand its market presence by entering new regions and increasing its product offerings in 2022[164]. - Future guidance suggests a revenue growth target of 10-15% for the upcoming fiscal year[164]. Corporate Governance - The board consists of 9 directors, including 3 independent directors, ensuring compliance with governance regulations[155]. - The supervisory board has 3 members, including 1 employee representative, to ensure independent oversight of company operations[156]. - The company is committed to maintaining high corporate governance standards to protect shareholder interests[155]. - The company has not faced any penalties from securities regulatory authorities in the past three years[175]. - The company’s profit distribution principles align with regulatory requirements, ensuring protection of shareholder interests, particularly for minority investors[192]. Strategic Initiatives - The company aims to optimize its industrial structure and deepen its business development in the intelligent material management sector, targeting the smart medical project business segment[41]. - The company plans to enhance collaboration between upstream and downstream industries to improve operational efficiency and product development[151]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[164]. - The company plans to implement new marketing strategies aimed at increasing brand awareness and customer engagement, with a budget allocation of 50 million RMB[171]. - The company aims to improve operational efficiency, targeting a 15% reduction in costs through process optimization initiatives[171].